Literature DB >> 35747539

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Five New Things.

Chafic Karam1.   

Abstract

Purpose of Review: The purpose of this review is to give an update on chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Recent findings: There are several recent developments in CIDP, the major one being the 2021 second revision of the European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Other updates address therapy in CIDP, antibodies, serum neurofilament light chain, chronic immune sensory polyradiculopathy (CISP) and CIDP mimics. Summary: CIDP criteria continue to be refined and some disorders are now excluded from the classification. Treatment options are expending and promising biomarkers are being studied.
© 2022 American Academy of Neurology.

Entities:  

Year:  2022        PMID： 35747539      PMCID： PMC9208411          DOI： 10.1212/CPJ.0000000000001150

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


  23 in total

1.  Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis.

Authors:  Ari Breiner; Pierre R Bourque; Jeffrey A Allen
Journal:  Muscle Nerve       Date:  2019-05-17       Impact factor: 3.217

2.  Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

Authors:  Gwen G A van Lieverloo; Luuk Wieske; Camiel Verhamme; Alexander F J Vrancken; Pieter A van Doorn; Zuzanna Michalak; Christian Barro; Ivo N van Schaik; Jens Kuhle; Filip Eftimov
Journal:  J Peripher Nerv Syst       Date:  2019-04-29       Impact factor: 3.494

3.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ivo N van Schaik; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Orell Mielke; Billie L Durn; David R Cornblath; Ingemar S J Merkies
Journal:  Lancet Neurol       Date:  2017-11-06       Impact factor: 44.182

4.  Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy.

Authors:  Ari Breiner; Thomas H Brannagan
Journal:  Muscle Nerve       Date:  2013-12-11       Impact factor: 3.217

5.  CIDP diagnostic pitfalls and perception of treatment benefit.

Authors:  Jeffrey A Allen; Richard A Lewis
Journal:  Neurology       Date:  2015-07-15       Impact factor: 9.910

6.  Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Peter D Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Richard Hughes; Norman Latov; Ingemar Merkies; Pieter van Doorn
Journal:  Arch Neurol       Date:  2010-09

7.  Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia.

Authors:  M Sinnreich; C J Klein; J R Daube; J Engelstad; R J Spinner; P J B Dyck
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

8.  Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

Authors:  Ivo N van Schaik; Orell Mielke; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Billie L Durn; David R Cornblath; Ingemar S J Merkies
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-07-03

9.  CIDP mimics: a case series.

Authors:  Orly Moshe-Lilie; Erik Ensrud; Thomas Ragole; Chahin Nizar; Diana Dimitrova; Chafic Karam
Journal:  BMC Neurol       Date:  2021-02-28       Impact factor: 2.474

10.  Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Authors:  S R M Bus; M C Broers; F Eftimov; I M Lucke; C Bunschoten; G G A van Lieverloo; M E Adrichem; R van Veen; L Wieske; H F Lingsma; H S Goedee; W L van der Pol; I N van Schaik; P A Van Doorn; B C Jacobs
Journal:  J Neurol       Date:  2021-06-26       Impact factor: 6.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.